AEON: the balance sheet

MyFinsight

Balance Sheets	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Cash and cash equivalents	6,243	3,006	5,927	8,439
Prepaid expenses and other current assets	382	392	1,485	1,823
Total current assets	6,625	3,398	7,412	10,262
Property and equipment, net	142	162	181	200
Operating lease right-of-use asset	992	1,052	1,112	1,171
Other assets	871	948	29	29
Total assets	8,630	5,560	8,734	11,662

Accounts payable	1,481	942	2,525	3,907
Accrued clinical trials expenses	1,173	1,426	1,524	1,675
Accrued compensation	1,832	2,872	1,547	546
Other accrued expenses	2,183	1,657	2,632	3,001
Total current liabilities	6,669	6,897	8,228	9,129
Convertible notes at fair value, including related party amount of 1,542 and 34,600 at march 31, 2026 and december 2025, respectively	1,542	34,600	17,051	15,174
Operating lease liability	825	893	957	1,020
Derivative liability	NaN	14,879	NaN	NaN
Contingent consideration liability	NaN	NaN	NaN	100
Warrant liabilities	16,308	3,276	2,338	2,122
Contingent consideration liability	38	42	32	69
Total liabilities	25,382	60,587	28,606	27,514
Class a common stock, 0.0001 par value 1,040,000,000 and 500,000,000 shares authorized at march 31, 2026 and december 31, 2025, and 25,303,058 and 12,105,902 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively	10	9	9	9
Additional paid-in capital	465,850	415,783	413,801	413,283
Accumulated deficit	-482,612	-470,819	-433,682	-429,144
Total stockholders' deficit	-16,752	-55,027	-19,872	-15,852
Total liabilities and stockholders' deficit	8,630	5,560	8,734	11,662

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.